Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
about
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapyDifferential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancerEpidermal growth factor receptor translocation to the mitochondria: regulation and effect.Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityThe epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.Dynamics of tumor hypoxia in response to patupilone and ionizing radiationRoles of autophagy in cetuximab-mediated cancer therapy against EGFR.Genetic modifiers of EGFR dependence in non-small cell lung cancer.Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.Lack of in vivo antibody dependent cellular cytotoxicity with antibody containing gold nanoparticlesThe anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1αTumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-ARole of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomamiR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma.Targeting the hypoxia-inducible factor (HIF) pathway in cancer.HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER InhibitorsEstablishment and characterization of primary lung cancer cell lines from Chinese population.FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growtFrom tumor hypoxia to cancer progression: the implications of hypoxia-inducible factor-1 expression in cancersCetuximab induces eme1-mediated DNA repair: a novel mechanism for cetuximab resistance.Chronic sun exposure-related fusion oncogenes EGFR-PPARGC1A in cutaneous squamous cell carcinoma.Identifying Determinants of EGFR-Targeted Therapeutic Biochemical Efficacy Using Computational Modeling.Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
P2860
Q27851729-52E71742-C3B8-438C-A45E-19DC270EFCEDQ28476652-C9FDA4A3-688E-4C88-9525-A684FA5621C3Q28477182-9049952A-2495-44BB-A328-F2F39CD0D8A8Q30433793-844DFB7A-411F-4F71-AA7A-C67E7E4985A4Q33576236-F4ECC0AF-093B-414C-9022-8D11CA60EADAQ34036041-E5411D3D-B0F9-4147-ACC7-DD8EC1283DB6Q34103230-9ECA08E7-BA4B-44FE-AF3E-8F937D2FAA86Q34516719-1501C8C0-64A7-453F-8C1F-2D337760F194Q34576155-087DE74E-7C83-41D3-8C96-32430B96F64EQ34832117-9844D4F3-E5DF-4F23-BF54-39CFA436B732Q35009672-136ECA91-D602-4328-8075-D60721FC2BEEQ35653952-D1A4EB51-CED9-4DA5-B6BD-117F955AC7B6Q35992051-303B65B8-8D1A-4E94-93B3-A5EA125DF92EQ36048159-2D669AE9-8CB0-4D14-9F9B-058354ABD9FAQ37080964-AD9362FC-27F7-4CF2-AAD3-45CB38F517F7Q37262663-C53CE34D-D3AF-44ED-976E-A77F0D14AD57Q37351498-9FBDEB90-8FE2-4A09-AA0F-257E8B7A8019Q37475020-E3CDE6A9-C03C-405B-A101-5981F1A4E071Q37587446-2855C68F-8DCB-44DD-80B0-A982B62FF821Q37668572-27EC130E-5A98-42B8-8C60-CFB84A537A40Q37728841-FBC8424A-44F8-42CB-8E33-32ADAE3BFE12Q38743209-DB284967-5343-46BA-BB09-4A8D108A0766Q38998235-725F7BFF-5DF9-4832-A139-D81C26EB0DCCQ41767159-A68FB20F-54B8-4BAE-B4E1-735C5373EE8BQ41816821-C3A8AD91-4FF5-4A1C-9CCC-C46BF2D3211EQ42157310-1C0D3B45-BB27-4315-97CB-95E2FC178E51Q42418384-EF48DCD0-F4C1-4F8F-823B-EC87FBEA41EFQ47121798-1AD2765D-E6E9-4130-9080-F76445091F3DQ54977360-647558AE-9E42-4A42-883D-FFE0E05F659F
P2860
Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Responses of cancer cells with ...... poxia-inducible factor-1alpha.
@ast
Responses of cancer cells with ...... poxia-inducible factor-1alpha.
@en
type
label
Responses of cancer cells with ...... poxia-inducible factor-1alpha.
@ast
Responses of cancer cells with ...... poxia-inducible factor-1alpha.
@en
prefLabel
Responses of cancer cells with ...... poxia-inducible factor-1alpha.
@ast
Responses of cancer cells with ...... poxia-inducible factor-1alpha.
@en
P2093
P2860
P356
P1433
P1476
Responses of cancer cells with ...... poxia-inducible factor-1alpha.
@en
P2093
P2860
P2888
P356
10.1186/1476-4598-6-63
P577
2007-10-11T00:00:00Z
P5875
P6179
1052951884